

Bach Pharma, Inc. and Destum Partners, Inc. - Corporate Development Initiatives

NORTH ANDOVER, Massachusetts – October 31, 2011 – Bach Pharma, Inc. (Bach), a privately held drug development company focused on therapeutics for homeostatic oxidative related diseases, announces the selection of Destum Partners, Inc. to identify, evaluate, and secure strategic partnerships for Monosodium Luminol (GVT[®]). GVT[®] is currently approved for use in the Commonwealth of Independent States (CIS) countries including Russia, and a number of Central and Eastern European (CEE) countries as a standard of care treatment for select cancer tumors, as an immunomodulator, an anti-inflammatory agent, and as an adjunct to chemotherapy and radiation treatments. A broad intellectual property estate owned by Bach covers compositions and uses of GVT[®] for the treatment of life threatening oxidative stress related diseases.

Monosodium Luminol has been studied extensively through approximately sixty five (65) human clinical trials in numerous therapeutic areas ranging from cancer therapy and wound healing, to treatments for diseases related to the central nervous system (CNS). While the therapeutic breadth is impressive, Destum Partners will focus on select strategic partnering opportunities. In particular, significant emphasis will be placed on securing partnerships for the advancement of the oncology and CNS applications of GVT[®] and its derivatives. Destum Partners is actively seeking partnerships to begin commercialization and distribution of GVT[®] in the CIS and select CEE countries, as well as partnerships focused on CNS related diseases.

Approvals are in place to annually treat over a half million cancer patients in the CIS countries alone, a very attractive market opportunity especially for an Eastern European partner. In CNS related diseases, GVT[®] is the subject of a phase I/II clinical study to treat ataxia-telangiectasia (A-T), a rare childhood genetic disorder, which currently has no effective treatment and leads to early complications of aging and death among its young patients. This study demonstrates strong pre-clinical support for its use in other CNS and/or Orphan diseases such as Parkinson's, Amyotrophic Lateral Sclerosis (ALS) and Friedreich's Ataxia.

"The Management Team and Board of Directors of Bach carefully evaluated all available options, and believe that the experience, industry focus, and the impressive track record of Destum Partners are ideally suited to meet our strategic partnering objectives", stated Mark Henry, CEO of Bach Pharma. Gareth Lugg, Managing Director and Co-Founder of Destum Partners commented, "It is very uncommon to find a drug such as Monosodium Luminol (GVT[®]) with such broad therapeutic potential, and with a massive body of clinical safety and efficacy data behind the compound. This drug offers a great opportunity for potential partners to secure a low risk asset that has significant revenue upside in the near term. Destum Partners has completed a compelling analysis of the current market potential in the geographical regions selected and is quickly moving forward with this opportunity."

About Bach Pharma

Bach Pharma, Inc. based in North Andover, MA is a pharmaceutical company engaged in the discovery, development, and commercialization of new therapeutics for the treatment of life threatening oxidative stress related diseases as well as other serious illnesses. Bach is a member of the MassBio Council and participates with the Massachusetts Life Sciences Center's Internship Challenge Program. Bach is a member of the US-Russian Chamber of Commerce of New England and pioneered the founding of the US-Russian Scientific Exchange Forum. The Foundation for the National Institutes of Health (FNIH), in partnership with the National Institutes of Health (NIH), the Institute of Medicine (IOM) and the Russian Academy of Sciences (RAS) of the Russian Federation, was created as a result of the 2009 U.S.-Russia Bi-Lateral Presidential Commission, which highlighted greater cooperation in the health sciences as a key theme. The Forum will promote and facilitate broader research collaboration in the biomedical and behavioral sciences between the U.S. and Russian scientific communities, with the goal of improving public health. Specifically, the Forum will strengthen joint

research activities related to disease control, treatment and prevention, clinical and translational research, and regulatory science, and the development of new health technologies.

Bach developed the proprietary manufacturing technologies for its proven phthalazinedione drug platform. Bach owns all of the intellectual property that encompasses this entire class of phthalazinediones as pharmaceutical agents. Monosodium Luminol is a subclass of phthalazinediones. Bach maintains one of the world's most active monosodium luminol research programs focused on specific compound platforms and their derivatives.

About Destum Partners

Based in Charlotte, NC, Destum Partners, Inc. is a boutique advisory and consulting firm designed to effectively meet the analytics and partnering demands of the biopharmaceutical and life sciences sectors. Destum serves an exclusive clientele dedicated to pushing the boundaries of technology innovation to improve the quality of life of humanity. Their clients range from multinational pharmaceutical corporations to private early stage biotechnology companies.

###

For more information about this opportunity, or to schedule an interview, please contact: Nick Klock Senior Director of Business Development at nklock@destumpartners.com. For additional information about Destum Partners please go to our web site at www.destumpartners.com.

For additional information about Bach Pharma please go to our web site at www.bachpharma.com. For information about this press release please email George Hillman at ghillman@bachpharma.com.